^
    1m
    The importance of IFNα2A (Roferon-A) in HSV-1 latency and T cell exhaustion in ocularly infected mice. (PubMed, PLoS Pathog)
    The absence of IFNα2A significantly reduced the levels of latency and T cell exhaustion but not time of reactivation compared with control mice. Our results suggest that blocking IFNα2A expression may be a useful tool in reducing latency and the subsequent side effects associated with higher levels of latency.
    Preclinical • Journal
    |
    IFNG (Interferon, gamma) • IFNA1 (Interferon Alpha 1) • IFNB1 (Interferon Beta 1)
    |
    IFNG expression
    |
    Roferon A (recombinant interferon alfa-2a)
    1year
    Expression and purification of human interferon alpha 2a (IFNα2a) in the methylotrophic yeast Pichia pastoris. (PubMed, Protein Expr Purif)
    The biological activity of the P. pastoris-produced IFNα2a was confirmed in A549 and HT29 cells by monitoring transcriptional up-regulation of a panel of known interferon-stimulated genes (ISGs). Our results document that the P. pastoris expression system is a suitable system for producing biologically functional IFNα2a in a secreted form.
    Journal
    |
    IFNA1 (Interferon Alpha 1)
    |
    Roferon A (recombinant interferon alfa-2a)
    over2years
    Interferon Alpha Induces Cellular Autophagy and Modulates Hepatitis B Virus Replication. (PubMed, Front Cell Infect Microbiol)
    Despite of ISGs induction, HBV replication and gene expression in HepG2.2.15 cells, a cell model with continuous HBV replication, were slightly increased at high doses of IFNα-2a. In conclusion, our study indicates that IFNα-2a treatment may interfere with multiple intracellular signaling pathways, facilitate autophagy initiation, and block autophagic degradation, thereby resulting in slightly enhanced HBV replication.
    Journal
    |
    IFNA1 (Interferon Alpha 1)
    |
    Roferon A (recombinant interferon alfa-2a)
    4years
    Additive Effects of Zinc Chloride on the Suppression of Hepatitis A Virus Replication by Interferon in Human Hepatoma Huh7 Cells. (PubMed, In Vivo)
    Zinc chloride inhibits HAV replication and has additive effects on the anti-HAV activities of interferon.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • BIRC3 (Baculoviral IAP repeat containing 3) • MAPK1 (Mitogen-activated protein kinase 1) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • IL1B (Interleukin 1, beta)
    |
    Roferon A (recombinant interferon alfa-2a)
    over4years
    Peptide vaccinations elicited strong immune responses that were reboosted by anti-PD1 therapy in a patient with myxofibrosarcoma. (PubMed, Cancer Immunol Immunother)
    The patient's immune responses weakened after surgical resection; however, they were reboosted following the administration of nivolumab combined with peptide vaccinations. Thus, anti-PD1 therapy combined with peptide vaccinations might be beneficial, as suggested by the observations in this sarcoma patient.
    Clinical • Journal
    |
    BIRC5 (Baculoviral IAP repeat containing 5)
    |
    Opdivo (nivolumab) • Roferon A (recombinant interferon alfa-2a)
    almost5years
    A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=158, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Clinical • Trial completion • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PD-1 (Programmed cell death 1)
    |
    EGFR mutation • BRAF mutation • BRAF V600 • ALK rearrangement
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • Gazyva (obinutuzumab) • Pegasys (pegylated interferon α -2a) • Roferon A (recombinant interferon alfa-2a)
    5years
    A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=158, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Aug 2019 --> Nov 2019 | Trial primary completion date: Aug 2019 --> Nov 2019
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PD-1 (Programmed cell death 1)
    |
    EGFR mutation • BRAF mutation • BRAF V600 • ALK rearrangement
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • Gazyva (obinutuzumab) • Pegasys (pegylated interferon α -2a) • Roferon A (recombinant interferon alfa-2a)
    over5years
    A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1; N=158; Active, not recruiting; Sponsor: Hoffmann-La Roche; Trial completion date: Feb 2019 --> Aug 2019; Trial primary completion date: Feb 2019 --> Aug 2019
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PD-1 (Programmed cell death 1)
    |
    EGFR mutation • BRAF mutation • BRAF V600 • ALK rearrangement
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • Gazyva (obinutuzumab) • Pegasys (pegylated interferon α -2a) • Roferon A (recombinant interferon alfa-2a)